Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · IEX Real-Time Price · USD
15.50
+0.82 (5.59%)
Apr 23, 2024, 4:00 PM EDT - Market closed
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for Arcus Biosciences stock have an average target of 41.78, with a low estimate of 23 and a high estimate of 70. The average target predicts an increase of 169.55% from the current stock price of 15.50.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 25, 2024.
Analyst Ratings
The average analyst rating for RCUS stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +222.58% | Mar 25, 2024 |
| Wedbush | Wedbush | Buy Reiterates $30 | Buy | Reiterates | $30 | +93.55% | Feb 22, 2024 |
| Wedbush | Wedbush | Buy Maintains $36 → $30 | Buy | Maintains | $36 → $30 | +93.55% | Jan 30, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $51 → $42 | Strong Buy | Maintains | $51 → $42 | +170.97% | Jan 30, 2024 |
| Wedbush | Wedbush | Buy Reiterates $36 | Buy | Reiterates | $36 | +132.26% | Jan 17, 2024 |
Financial Forecast
Revenue This Year
195.49M
from 117.00M
Increased by 67.09%
Revenue Next Year
169.94M
from 195.49M
Decreased by -13.07%
EPS This Year
-3.59
from -4.15
EPS Next Year
-4.35
from -3.59
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 527.3M | 551.1M | 182.7M | 509.9M | 1.1B |
| Avg | 195.5M | 169.9M | 134.6M | 340.2M | 616.1M |
| Low | 98.0M | 88.2M | 88.2M | 268.5M | 365.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 350.7% | 181.9% | 7.5% | 278.8% | 216.6% |
| Avg | 67.1% | -13.1% | -20.8% | 152.7% | 81.1% |
| Low | -16.2% | -54.9% | -48.1% | 99.5% | 7.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.34 | -2.53 | -1.65 | -1.23 | 3.40 |
| Avg | -3.59 | -4.35 | -3.80 | -1.89 | 1.16 |
| Low | -4.82 | -5.87 | -5.99 | -2.48 | -0.94 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.